Connective Tissue Oncology Society

(713) IDENTIFICATION OF NOVEL ONCOGENES IN LIPOSARCOMA USING TRANSCRIPTIONAL PROFILING AND ARRAY-BASED COMPARATIVE GENOMIC HYBRIDISATION
D M Thomas¹; T Morgan¹; P F Choong¹; I Dickinson³; J Slavin⁴; S Schlicht⁴; G Powell⁴; P Crowe²
¹Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ²Prince of Wales Hospital, Sydney, NSW, Australia; ³Wesley Hospital, Brisbane, Queensland, Australia; ⁴St Vincents Hospital, Melbourne, Victoria, Australia

(617) DUAL ROLE OF CD99 AS ONCOSUPPRESSOR OR ONCOGENE IN OSTEOSARCOMA AND EWING’S SARCOMA: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS.

* K Scotlandi¹; M Manara¹; A Rocchi¹; M Zuntini¹; F Nardi¹; L Cantiani¹; M Sciandra¹; G Nicoletti¹; P Lollini²; P Picci¹
¹Istituti Ortopedici Rizzoli, Bologna, , Italy; ²Universita di Bologna, Bologna, , Italy

(556) RAD51 OVEREXPRESSION CONTRIBUTES TO CHEMORESISTANCE IN HUMAN SOFT TISSUE SARCOMA (STS); A ROLE FOR P53/AP-2 TRANSCRIPTIONAL REGULATION
J Hannay; J Liu; S Bolshakov; D Yu; A Lazar; * R Pollock; * D Lev
MD Anderson Cancer Center, Houston, Texas, United States

(711) CXCR4 RECEPTOR IS ASSOCIATED WITH HEMATOGENOUS METASTASES IN LEYOMIOSARCOMA (LMS), PLEOMORPHIC SARCOMA (PMS) AND LIPOSARCOMA (LPS).
S Aliberti¹; G Grignani¹; A Pisacane¹; G Cavalloni¹; M Motta²; Y Pignochino¹; I Sarotto¹; P Allione¹; B Torchio²; M Risio¹; M Aglietta¹
¹Institute for Cancer Research and Treatment, Candiolo, Torino, Italy; ²ASO Mauriziano, Torino, , Italy

2:25 PM–3:20 PM
Salon del Ridotto

Session 2 — Pathological and Molecular Diagnosis of Sarcomas

Moderator: Piero Picci, MD

(559) NOVEL EWING SARCOMA TRANSLOCATION IDENTIFIED IN CASE LACKING EWS GENE REARRANGEMENT
* M J O'Sullivan²; T L Ng²; T Nielsen¹; M Hayes²; P Sorensen²; D Horsman²
¹The University of British Columbia, Vancouver, BC, Canada; ²BC Cancer Agency and BC Cancer Research Centre, Vancouver, BC, Canada; ³BC Childrens Hospital, Vancouver, BC, Canada

(718) CORRELATION BETWEEN HISTOLOGY AND KIT/PDGFRA GENE STATUS IN IMATINIB TREATED GASTROINTESTINAL STROMAL TUMORS (GIST)
F Miselli; P Casieri; T Negri; M Orsenigo; M S Lagonigro; * A Gronchi; M Fiore; S Stacchiotti; R Bertulli; P G Casali; A Carbone; M A Perotti; E Tamborini; S Pilotti
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, , Italy

(590) CYCLOOXYGENASE-2 OVEREXPRESSION ASSOCIATED WITH A POOR PROGNOSIS IN CHONDROSARCOMAS
M Endo¹; T Matsumura²; U Yamaguchi¹; F Nakatani¹; A Kawai¹; H Chuman¹; Y Beppu¹; T Hasegawa²
¹National Cancer Center Hospital, Tokyo, , Japan; ²Sapporo Medical University School of Medicine, Sapporo, , Japan

3:35 PM–4:30 PM
Salon del Ridotto

Session 3 — Pediatric Sarcomas

Moderator: Paul Meyers, MD

(524) MICROARRAY ANALYSIS OF EWS/FLI IN EWING'S SARCOMA REVEALS A CRITICAL ROLE FOR NKX2.2 IN ONCOGENESIS

Leah A. Owen¹, Richard Smith¹, Deborah J. Trem¹, Jenny S. Wong⁴, Jennifer S. Whangbo⁴, Todd R. Golub⁵, Stephen L. Lessnick¹

¹Huntsman Cancer Institute, Salt Lake City, UT, United States; ²Primary Childrens Medical Center, Salt Lake City, UT, United States; ³University of Utah, Salt Lake City, UT, United States; ⁴Dana Farber Cancer Institute, Boston, MA, United States; ⁵Broad Institute, Cambridge, MA, United States

(666) NON- METASTATIC OSTEOSARCOMA: RESPONSE BASED AUGMENTATION OF THERAPY
C L Schwartz; L H Wexler; M Devidas; L A Teot; A Goorin; H Grier; M Gebhard; L Steinherz; J Sato; J Healey; S Lipshultz; J Miser; R Womer; * P Meyers; * M Bernstein
Childrens Oncology Group, Arcadia, CA, United States

(743) PEDIATRIC LIMB SALVAGE WITH THE STANMORE NON-INVASIVE EXPANDABLE PROSTHESIS - THE UNITED STATES EXPERIENCE
E R Henderson; D Cheong; * G D Letson
Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

(610) A PRECLINICAL EVALUATION OF ZIO-201 (ISOPHOSPHORAMIDE MUSTARD (IPM)-LYSINE) IN SARCOMA.
E Kolb¹; P Gidwani¹; R P Gale²; * R Gorlick¹
¹Albert Einstein College of Medicine, Bronx, NY, United States; ²ZIOPHARM Oncology Inc, New York, NY, United States

4:30 PM–5:25 PM
Salon del Ridotto

Session 4 — Animal Models of Sarcomas

Moderator: Mario Capecchi, PhD

(606) REGIONS OF THE CANINE GENOME ASSOCIATED WITH OSTEOSARCOMA IDENTIFIED BY A WHOLE GENOME CASE-CONTROL ASSOCIATION STUDY.
K E Comstock¹; E K Karlsson²; C Wade²; E T Keller¹; E Lander²; * L H Baker¹; K Lindblad-Toh²
¹University of Michigan, Ann Arbor, MI, United States; ²Broad Institute of Harvard and MIT, Boston, MA, United States

(522) VEGF EXPRESSION CORRELATES WITH FAST GROWTH AND EARLY METASTASIS IN A NOVEL MODEL OF OSTEOSARCOMA
S Yang; H Yu; J Krygier; M P Mott; P H Wooley
Wayne State University, Detroit, MI, United States

(566) P53 MUTATION IS REQUIRED FOR SARCOMA DEVELOPMENT AND TUMOR MAINTENANCE IN MICE
* D G Kirsch¹; A Ventura²; M McLaughlin²; D Tuveson²; D Dinulescu²; P Santiago²; J Grimm¹; R Weissleder¹; T Jacks²
¹Massachusetts General Hosptial, Boston, MA, United States; ²Massachusetts Institute of Technology, Cambridge, MA, United States

5:25 PM–6:25 PM
Second Floor

Poster Viewing of Sessions 1-4

Session 1 — 544,545,549,563,585,614,642,671,672,679,686,689,697,698,700,704,720,733,734,747,748,764

Session 2 — 513,546,565,570,571,581,583,621,627,650,656,657,714

Session 3 — 551,552,553,600,705,710,719,735,739

Session 4 — 620,628

6:25 PM–6:40 PM
Salon del Ridotto

Session 5 — Fascinoma in CTOS: A Review

Moderator: Robert. Maki, MD

6:40 PM–7:15 PM
Second Floor

Poster Viewing of Session 5

Session 5 — 508,515,568,584,630,631,640,654,667,677,721,722,736,737,757,759,761

Friday, November 3
7:00 AM–8:00 AM Board Room	Executive Committee Meeting
8:00 AM–8:55 AM Salon del Ridotto	Session 6 — Initial Management and Surgery *Moderators: Silvie Bonvalot, MD,* *Alessandro Gronchi, MD*
	(530) SURGEON-LED BIOPSY WITH INTRAOPERATIVE FROZEN SECTION IS AN ACCURATE AND COST EFFECTIVE METHOD FOR INITIAL EVALUATION OF MUSCULOSKELETAL SARCOMAS. R U Ashford¹; S W McCarthy¹; R A Scolyer¹; S Bonar²; R Z Karim¹; P D Stalley¹ ¹Royal Prince Alfred Hospital, Sydney, NSW, Australia; ²Douglass Hanly Moir Pathology, Ryde, NSW, Australia
	(558) ISOLATED LIMB PERFUSION: A NOVEL DELIVERY SYSTEM FOR WILD TYPE P53 AND FIBER-MODIFIED ONCOLYTIC ADENOVIRUSES TO EXTREMITY SARCOMA J Hannay; D Yu; J Liu; * R Pollock; * D Lev MD Anderson Cancer Center, Houston, Texas, United States
	(637) AGGRESSIVE TREATMENT FOR LOCAL RECURRENCE OF ABDOMINAL SARCOMA – IS IT WORTH IT? I Nachmany; D Dayan; O Merimsky; G Lahat; J Klausner Tel Aviv Sourasky Medical Center, Tel Aviv, , Israel
8:55 AM–10:20 AM Salon del Ridotto	Poster Viewing of Session 6 Session 6 — 542,543,560,562,573,575,587,591,598,602,609,613,629,644,645,647,653,668,678,681,684,685,707,708,723,728,740
10:20 AM–11:15 AM Salon del Ridotto	Session 7 — Cytotoxic Chemotherapy *Moderators: Robert Benjamin, MD, Jean Yves Blay, MD*
	(611) INCIDENCE OF DELAYS IN CHEMOTHERAPY DUE TO METHOTREXATE TOXICITY IN TREATMENT OF OSTEOSARCOMA M Perisoglou; * B Seddon; S Daniels; N Mayne; * J Whelan University College Hospital, London, , United Kingdom
	(676) SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA: RESULTS FROM A RANDOMIZED PHASE II TRIAL M Schuler¹; D Pink¹; T Lindner¹; D Schoeler²; * J Hartmann³; S Micheel¹; * P Reichardt² ¹Robert Roessle Klinik Charite Campus Buch, Berlin, , Germany; ²Charite Campus Virchow Klinikum, Berlin, , Germany; ³Universitaet Tuebingen Medizinische Klinik, Tuebingen, , Germany
	(652) FACTORS INFLUENCING SARCOMA TREATMENT W G Ward¹; M T Cline¹; F J Dorey² ¹Wake Forest University School of Medicine, Winston Salem, North Carolina, United States; ²USC Keck School of Medicine, Los Angeles, California, United States
11:15 AM–12:30 PM Second Floor	Poster Viewing of Session 7 Session 7 — 511,561,564,569,576,589,596,608,612,623,634,639,675,676,693,695,699,702,712,716,725,728,729,732,744
12:30 PM–2:00 PM Board Room	Board of Directors Meeting
2:00 PM–3:00 PM Salon del Ridotto	Herman Suit Lecture: Mario Capecchi *Introduction: Junya Toguchida, MD, PhD*
3:00 PM–4:00 PM Salon del Ridotto	Session 8 — Imaging and Radiotherapy *Moderators: Haesun Choi, MD*
	(755) MULTIPLE TRACER PET ASSESSMENT OF TREATMENT RESPONSE IN SOFT TISSUE SARCOMA PATIENTS * E U Conrad, III; * J F Eary; * J E Butrynski; J M Link; A M Cizik; D M Mankoff; K A Krohn University of Washington, Seattle, WA, United States
	(577) MULTI-MODALITY IMAGING OF PREOPERATIVELY IRRADIATED SARCOMA PATIENTS DOES NOT PREDICT PATHOLOGICAL OUTCOME. * R Haas¹; L Dewit¹; * F Van Coevorden²; H Peterse³; C Loo⁴; R Valdés Olmos⁵ ¹The Netherlands Cancer Institute Department of Radiotherapy, Amsterdam, , Netherlands; ²The Netherlands Cancer Institute Department of Surgery, Amsterdam, , Netherlands; ³The Netherlands Cancer Institute Department of Pathology, Amsterdam, , Netherlands; ⁴The Netherlands Cancer Institute Department of Radiology, Amsterdam, , Netherlands; ⁵The Netherlands Cancer Institute Department of Nuclear Medicine, Amsterdam, , Netherlands
	(710) PET-CT FUSION IMAGING AND SUV ASSESSMENT USING MIMVISTA (RESISTING RECIST) * P Anderson MD Anderson Cancer Center, Houston, TX, United States
4:00 PM–4:45 PM Second Floor	Poster Viewing of Session 8 Session 8 — 529,531,536,586,599,601,604,635,662,663,669,673,674,682,703,731,745,756,762,763
4:45 PM–5:30 PM Salon del Ridotto	Diagnostic Competition *Daniel Vanel, MD***
5:30 PM–6:30 PM Salon del Ridotto	Members Business Meeting
7:00 PM–11:00 PM Palace Pisani Moretta	Reception and Dinner

Saturday, November 4
8:30 AM–9:30 AM Salon del Ridotto	Session 9 — Patient Advocacy Groups American College of Surgeons Oncology Group Canadian Sarcoma Group Children’s Oncology Group EORTC STBSG European and American Osteosarcoma Study Group GSF: Groupe Sarcome Français; GETO: Groupe d’Etudes des Tumeurs Osseuses Intergroup Coalition Against Sarcomas (ICAS) Italian Sarcoma Group Liddy Shriver Sarcoma Initiative Life Raft Group MHE Research Foundation Sarcoma Alliance Sarcoma UK The Sarcoma Working Group for RTOG 0630 Scandinavian Sarcoma Group
9:30 AM–10:30 AM Salon del Ridotto	Session 10 — The Presentation of Cooperative Groups: Prospective for Collaborations; Presentation of Ongoing Collaborative Projects
10:45 AM–12:00 PM Salon del Ridotto	Nina Axelrad Lecture: Lee J Helman, MD *Introduction: J unya Toguchida, MD, PhD,* *Luca Sangiorgi, MD, PhD*
1:00 PM–2:15 PM Salon del Ridotto	Session 11 — Molecular Biology for the Patients: Define New Targets? Predict Outcome? *Moderators: Ole Steen Nielsen, MD, Irene Andrulis, PhD*
	(619) PEDF INHIBITS OSTEOSARCOMA GROWTH AND METASTASIS E T Ek¹; C R Dass¹; K G Contreras¹; P F Choong¹ ¹St Vincents Hospital Melbourne, Melbourne, Victoria, Australia; ²Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
	(533) CLEAR CELL SARCOMA AND OTHER TRANSLOCATION-ASSOCIATED SARCOMAS ARE HIGHLY SENSITIVE TO HISTONE DEACETYLASE INHIBITOR MS-275 S Liu; M A Knowling; P Clarkson; J M Lubieniecka; H Cheng; * T O Nielsen University of British Columbia, Vancouver, BC, Canada
	(626) ANTI-TUMOR IMMUNITY AGAINST AUTOLOGOUS SYNOVIAL SARCOMA CELLS ELICITED IN VITRO BY CTLS RECOGNIZING THE TUMOR SPECIFIC ANTIGENS CREATED BY THE RECIPROCAL TRANSLOCATION OF SYT-SSX L L Chen¹; H Sang²; * Y Alan²; P P Lin²; C O Oyedeji²; E F Wu²; * J C Trent²; D M Steinert²; * S Patel²; * R S Benjamin²; M L Frazier² ¹Huntsman Cancer Institute of University of Utah, Salt Lake City, Utah, United States; ²M D Anderson Cancer Center of the University of Texas, Houston, Texas, United States
	(742) A SOLUBLE WNT RECEPTOR SHOWS ANTI-TUMOR ACTIVITY IN OSTEOSARCOMA Y Guo²; X Zi¹; B Sworder¹; H Pamela¹; J Xie¹; K Ivan²; * B H Hoang¹ ¹University of California Irvine, Orange, CA, United States; ²Children Hospital of Orange County, Orange, CA, United States
2:15 PM–3:30 PM Salon del Ridotto	Session 12 — Surgery, Cytotoxic and Targeted Therapies on GIST *Moderators: Ian Judson, MD,* *George Demetri, MD*
	(618) THE UPDATED OUTCOMES OF METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS TREATED SURGICALLY AFTER RESPONSE TO TARGETED THERAPY WITH IMATINIB (IM) * P Rutkowski¹; Z I Nowecki¹; P Nyckowski²; W Dziewirski¹; U Grzesiakowska¹; A Nasierowska-Guttmejer¹; W Michej¹; Z Zurawski¹; M Krawczyk²; * W Ruka¹ ¹Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, , Poland; ²Medical University, Warsaw, , Poland
	(641) INITIAL RESULTS OF A MULTICENTER SINGLE ARM PHASE 2 STUDY OF AMG 706, AN ORAL MULTI-KINASE INHIBITOR, FOR THE TREATMENT OF ADVANCED IMATINIB-RESISTANT GASTROINTESTINAL STROMAL TUMORS (GIST) * R Benjamin¹; * P Schöffski²; * J T Hartmann³; * B N Bui⁴; * J Duyster⁵; * S Schuetze⁶; * J Blay⁷; * P Reichardt⁸; * L Rosen⁹; * K Skubitz¹⁰; M Eschenberg¹¹; D Stepan¹¹; * L Baker⁶ ¹MD Anderson Cancer Center, Houston, TX, United States; ²University Hospital Gasthuisberg, Leuven, , Belgium; ³Tubingen University Medical Center II, Tübingen, , Germany; ⁴Fondation Bergonie, Bordeaux, , France; ⁵Technical University of Munich, Munich, , Germany; ⁶University of Michigan, Ann Arbor, MI, United States; ⁷Centre Leon Berard, Lyon, , France; ⁸Charite Campus Buch, Berlin, , Germany; ⁹Premiere Oncology, Santa Monica, CA, United States; ¹⁰University of Minnesota, Minneapolis, MN, United States; ¹¹Amgen Inc, Thousand Oaks, CA, United States
	(643) COMPARATIVE OUTCOMES IN PATIENTS WITH METASTATIC GIST TREATED WITH IMATINIB AT MAJOR SARCOMA CENTERS FROM THE INTERGROUP COALITION AGAINST SARCOMAS (ICAS) STUDY (S0033). * E C Borden⁶; C J Rankin¹; * C Fletcher²; * R Benjamin⁵; * M von Mehren⁴; * V Bramwell³; J Crowley¹; * G D Demetri² ¹SWOG Biostatistics, Seattle, WA, United States; ²CALGB, Boston, MA, United States; ³NCIC, Calgary, Alberta, Canada; ⁴ECOG, Philadelphia, PA, United States; ⁵MD Anderson, Houston, TX, United States; ⁶SWOG, Cleveland, OH, United States
	(661) PREDICTING TOXICITIES FOR PATIENTS WITH ADVANCED GASTRO-INTESTINAL STROMAL TUMORS (GIST) TREATED WITH IMATINIB: AN EORTC-ISG-AGITG STUDY. * M M Van Glabbeke¹; * J Verweij²; * P G Casali³; J Simes⁴; A Le Cesne⁵; * P Reichardt⁶; R Issels⁷; * I R Judson⁸; * A T van Oosterom⁹; * J Blay¹⁰ ¹EORTC Data Center, Brussels, , Belgium; ²Erasmus University Medical Center, Rotterdam, , Netherlands; ³Istituto Tumori, Milano, , Italy; ⁴NHMRC Clinical Trials Centre, University of Sydney, , Australia; ⁵Institut Gustave Roussy, Villejuif, , France; ⁶Charite Campus Buch, Berlin, , Germany; ⁷Klinikum Grosshadern, Munich, , Germany; ⁸Royal Marsden Hospital, London, , United Kingdom; ⁹University Hospital Gasthuisberg, Leuven, , Belgium; ¹⁰Center Leon Berard, Lyon, , France
3:30 PM–4:30 PM Salon del Ridotto	Poster Viewing of Session 11 and 12 Session 11 - 525,526,528,538,539,550,555,557,578,579,593,595,597,616,638,660,664,688,701,709,738,765 Session 12 – 646,648,724,727,730
4:30 PM–5:50 PM Salon del Ridotto	Session 13 — Surgery in Sarcomas *Moderators: R. Lor Randall, MD,* Jay Wunder, MD**
	(574) AGGRESSIVE EXTRA-ABDOMINAL FIBROMATOSIS: CAN AGGRESSIVE MANAGEMENT BE AVOIDED IN A SUBGROUP OF PATIENTS ? * S Bonvalot¹; H Eldweny¹; V Haddad¹; * A Le Cesne¹; G Missenard¹; P Terrier¹; * O Oberlin¹; * J Blay²; C Le Pechoux¹ ¹Institut Gustave Roussy, Villejuif, , France; ²Centre Leon Berard, Lyon, , France
	(649) MYXOID LIPOSARCOMA:PROGNOSTIC FACTORS AND SURVIVAL IN A SERIES OF PATIENTS TREATED AT A SINGLE INSTITUTION. M Fiore; F Grosso; S Lo Vullo; C Mussi; * S Stacchiotti; P Collini; L Lozza; L Mariani; * P G Casali; * A Gronchi Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, , Italy
	(750) CLINICAL UTILITY OF A NEW CLASSIFICATION OF SURGICAL MARGINS * E Y Cheng¹; P Zwolak¹; C T Le²; J C Manivel³; K E Dusenbery⁴; D R Clohisy¹; * K M Skubitz⁵; R C Thompson¹ ¹University of Minnesota Cancer Center Orthopaedic Surgery, Minneapolis, Minnesota, United States; ²Univ MN Department Biostatistics, Minneapolis, Minnesota, United States; ³Univ MN Pathology, Minneapolis, MN, United States; ⁴Univ MN Radiation Oncology, Minneapolis, MN, United States; ⁵Univ MN Medical Oncology, Minneapolis, MN, United States
	(751) SURGERY VS RADIOTHERAPY IN NONMETASTATIC EWING’S SARCOMA OF THE EXTREMITIES: EXPERIENCE OF A SINGLE INSTITUTION * N Fabbri; G Bacci; S Ferrari; A Longhi; D Donati; M Manfrini; E Barbieri; P Picci; M Mercuri; F Bertoni Istituto Ortopedico Rizzoli, Bologna, , Italy
5:50 PM–6:50 PM Second Floor	Poster Viewing of Session 13 Session 13 – 509,510,518,519,520,532,534,535,540,541,572,582,588,592,605,607,615,632,659,683,687,706,741,746,749,753,754,760